ARQ-154

Phase 2Small molecule

AArcutis Biotherapeutics, Inc.

ARQ-154 is one of 45 small molecule programs targeting Psoriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Seborrheic DermatitisActive, not recruiting

PsoriasisPhase 1

Active, not recruiting

Seborrheic DermatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Preclinical

37 2

Cosentyx

Novartis

Preclinical

53 3

Bimzelx

UCB

Preclinical

17 4

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 5

Remicade

OOrganon and Co

Preclinical

20 6

Siliq

BBausch Health Americas, Inc.

Preclinical

14 7

Victoza

Novo Nordisk

Preclinical

2 8

Lovenox

Sanofi

Preclinical

1 9

Olux

HHarrow Inc

Preclinical

4 10

ARQ-154

AArcutis Biotherapeutics, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Psoriasis

NCT07340216

Clinical

Trials by Indication[1]

Seborrheic Dermatitis1 trial

Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

Completed·AArcutis Biotherapeutics, Inc.·Phase 2·NCT04445987·408 enrolled

Psoriasis1 trial

Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis

Recruiting·AArcutis Biotherapeutics, Inc.·Phase 1·NCT07340216·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ARQ-154. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARQ-154 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARQ-154. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arcutis Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AArcutis Biotherapeutics, Inc.

ARQ-154

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Seborrheic Dermatitis1 trial

Psoriasis1 trial

References

Drug Info

Quick Facts

Related News